



NDA 21621/S-10

SUPPLEMENT APPROVAL

Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Attention: Jennifer Norman, RPh
7050 Camp Hill Road
Mail Stop III
Fort Washington, PA 19034-2299

Dear Ms. Norman:

Please refer to your supplemental new drug application (sNDA) dated July 30, 2020 and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Children's Zyrtec (cetirizine hydrochloride) 2.5 mg and 10 mg chewable tablets.

This "Prior Approval" supplemental new drug application provides for the reformulation of Children's Zyrtec (cetirizine hydrochloride) 10 mg chewable tablet and the introduction of a new 2.5 mg chewable tablet.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL) as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling described in the table below and must be in the "Drug Facts" format (21 CFR 201.66), where applicable.

Submitted Draft Labeling	Date Submitted
2.5 mg – 12-count carton	11/27/2020
2.5 mg – 24-count carton	11/27/2020
2.5 mg – 6-count blister mat	11/27/2020
10 mg – 24-count carton	11/27/2020
10 mg – 48-count carton	11/27/2020
10 mg – 6-count blister mat	11/27/2020

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.¹ For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 21621/S-10** .” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.² Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

¹ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

² <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

If you have any questions, call Sherry Stewart, PharmD, Senior Regulatory Project Manager, at (301) 796-9618.

Sincerely,

{See appended electronic signature page}

Nushin Todd, MD, PhD
Deputy Director (Acting)
Division of Nonprescription Drugs I
Office of Nonprescription Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NUSHIN F TODD
11/30/2020 05:08:34 PM